84 Grants (Page 2 of 4)
2008
ENDOTHELIN-1 IN NORMAL AND PATHOLOGICAL BONE REMODELING
Guise, Theresa A
National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (ID: 5R01DK067333-04), $52,420USD, 02/01/2005 -- 12/31/2009
 
PROSTATE CANCER BONE METASTASES: ROLE OF ADRENOMEDULLIN
Guise, Theresa A
National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (ID: 5R01DK065837-04), $333,010USD, 04/01/2005 -- 03/31/2010
 
TGFbeta IN THE BONE MICROENVIRONMENT: ROLE IN TUMOR METASTASIS
Guise, Theresa A
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 2R01CA069158-12A1), $276,088USD, 04/01/1996 -- 11/30/2012
2007
Breast Cancer Osteolysis--Regulation of PTHrP by TGFBeta
Guise, Theresa A
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 3R01CA069158-11S1), $128,298USD, 04/01/1996 -- 11/30/2007
 
ENDOTHELIN-1 IN NORMAL AND PATHOLOGICAL BONE REMODELING
Guise, Theresa A
National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (ID: 5R01DK067333-03), $289,195USD, 02/01/2005 -- 12/31/2008
 
PROSTATE CANCER BONE METASTASES: ROLE OF ADRENOMEDULLIN
Guise, Theresa A
National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (ID: 5R01DK065837-03), $339,805USD, 04/01/2005 -- 03/31/2010
2006
ENDOTHELIN-1 IN NORMAL AND PATHOLOGICAL BONE REMODELING
Guise, Theresa A
National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (ID: 5R01DK067333-02), $297,833USD, 02/01/2005 -- 12/31/2008
 
PROSTATE CANCER BONE METASTASES: ROLE OF ADRENOMEDULLIN
Guise, Theresa A
National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (ID: 5R01DK065837-02), $349,954USD, 04/01/2005 -- 03/31/2010
2005
Breast Cancer Osteolysis--Regulation of PTHrP by TGFBeta
Guise, Theresa A
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R01CA069158-11), $261,853USD, 04/01/1996 -- 11/30/2007
 
ENDOTHELIN-1 IN NORMAL AND PATHOLOGICAL BONE REMODELING
Guise, Theresa A
National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (ID: 1R01DK067333-01A1), $304,667USD, 02/01/2005 -- 12/31/2008
 
Endothelin-1 in normal and pathological bone remodeling (R01DK067333; Guise, PI; 20% effort)
Guise, Theresa A
National Institutes Of Health (Niddk), $1,216,000, 2005 -- 2008
 
Inhibition of Breast Cancer Bone Metastases with Anti-hypoxic Treatment (Guise, PI)
Guise, Theresa A
Mary K. Ash Foundation, $100,000, 2005 -- 2007
 
PROSTATE CANCER BONE METASTASES: ROLE OF ADRENOMEDULLIN
Guise, Theresa A
National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (ID: 1R01DK065837-01A2), $358,081USD, 04/01/2005 -- 03/31/2010
 
Prostate Cancer Metastases to Bone: Role of Andrenomedullin (R01 DK065837) (Guise, PI 20% effort)
Guise, Theresa A
National Institutes Of Health (Niddk), $1,790,000, 2005 -- 2010
2004
Breast Cancer Osteolysis--Regulation of PTHrP by TGFBeta
Guise, Theresa A
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R01CA069158-10), $261,383USD, 04/01/1996 -- 03/31/2006
 
Effects of a high bone turnover state induced by estrogen deficiency on the development and progression of breast cancer and bone metastases
Guise, Theresa A
V Foundation, $300,000, 2004 -- 2007
 
Inhibition of prostate cancer bone metastases with endothelin receptor blockade plus bisphonate antiresorptive: preclinical testing and molecular mechanisms
Guise, Theresa A
Prostate Cancer Foundation, $75,000, 2004 -- 2005
 
Preclinical Evaluation of Serine/Threonine Kinase Inhibitors Against Prostate Cancer Metastases
Guise, Theresa A
Us Rmy Prostate Cancer Program Idea Award Pc040341, $571,521 (Guise, PI,, 2004 -- 2007
 
The Effects of aromatase inhibition on estrogen targets: breast bone and growth hormone-1GF-1 axis
Guise, Theresa A
Novartis Pharmaceuticals, $164,778 Awarded for, 2004 -- 2007
2003
Breast Cancer Osteolysis--Regulation of PTHrP by TGFBeta
Guise, Theresa A
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R01CA069158-09), $260,924USD, 04/01/1996 -- 03/31/2006
 
'Targeting the lethal phenotype of metastatic prostate cancer'
Guise, Theresa A
Department Of Defense, $300,000, Feb 1, 2003 -- Jan 31, 2006
 
Targeting the lethal phenotype of metastatic prostate cancer. (Guise and Chirgwin, Co-PI, 10% effort)
Guise, Theresa A
Department Of Defense, Subcontract From Emory University, Direct costs: $300,0, 2003 -- 2006
 
The effects of aromatase inhibition on estrogen targets: breast, bone and growth hormone-1GF-1 axis
Guise, Theresa A
University Of Virginia Cancer Center, $320,000, 2003 -- 2005
2002
Breast Cancer Osteolysis--Regulation of PTHrP by TGFBeta
Guise, Theresa A
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R01CA069158-07), $71,570USD, 04/01/1996 -- 09/30/2002
 
Breast Cancer Osteolysis--Regulation of PTHrP by TGFBeta
Guise, Theresa A
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 7R01CA069158-08), $178,028USD, 04/01/1996 -- 03/31/2006